C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20 536 patients in the Heart Protection Study Heart Protection.

Slides:

Advertisements

Similar presentations

Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.

Advertisements

Baseline characteristics of participants presenting with or without peripheral artery disease (PAD) Heart Protection Study Group J Vasc Surg 2007;45:

Number of participants with diabetes by trial Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:

Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)

Beyond the Laboratory by Julian P.J. Halcox, and John E. Deanfield Circulation Volume 109(21 suppl 1):II-42-II-48 June 1, 2004 Copyright © American Heart.

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from participants in 26 randomised trials Lancet 2010;

Volume 376, Issue 9753, Pages (November 2010)

Pharmacogenetics and future drug development and delivery

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials Cholesterol.

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised.

Volume 376, Issue 9734, Pages (July 2010)

Thank God for Richard Dawkins?

Long-term effects of hormone replacement therapy

Low-level laser therapy for neck pain

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients Evan Stein, MD, Harold Bays, MD, Michael Koren,

Volume 376, Issue 9734, Pages (July 2010)

Volume 375, Issue 9709, Pages (January 2010)

Long-term effects of hormone replacement therapy

Political factors behind US global AIDS programmes slow-down

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

Aspirin in the prevention of cancer – Author's reply

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials Cholesterol.

Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes:

Gene therapy—where are we?

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta- analysis of individual participant data from randomised trials

Age-specific relevance of usual blood pressure to vascular mortality

Think Again About Cholesterol Survey

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised.

Statins for prevention of stroke

A next-generation Alzheimer's centre for Madrid

Organisation of the care of patients with heart failure

Incident diabetes in clinical trials of antihypertensive drugs

HIV myths should not be resuscitated

Statins and C-reactive protein

Volume 26, Issue 2, Pages (February 2018)

Volume 379, Issue 9822, Pages (March 2012)

General Practice Research Database for prescribing analysis

Adrian Martineau The Lancet Respiratory Medicine

Risk thresholds for alcohol consumption

Volume 375, Issue 9725, Pages (May 2010)

MRC/BHF Heart Protection Study

Confessions of a journal junkie

Infant-feeding patterns and HIV-1 transmission

Volume 376, Issue 9753, Pages (November 2010)

Recommendations for the management of patients with homozygous familial hypercholesterolaemia: Overview of a new European Atherosclerosis Society consensus.

Volume 371, Issue 9627, Pages (May 2008)

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials Cholesterol.

Telling it like it isn't: truth and lies in a post-9/11 world

Baseline Characteristics by Baseline N-BNP Level

Volume 382, Issue 9894, Pages (August 2013)

Volume 377, Issue 9771, Pages (March 2011)

Thank God for Richard Dawkins?

Heart Protection Study Collaborative Group Lancet 2011;377:469-76

Estimated 5-year rate of a first major vascular event (MVE), major coronary event (MCE),or vascular death in univariate and multivariate risk subgroups.

Low-technology approaches

Volume 379, Issue 9822, Pages (March 2012)

Muh Geot Wong, Vlado Perkovic The Lancet Diabetes & Endocrinology

ACST: which subgroups will benefit most from carotid endarterectomy?

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

Prescription for change

Volume 373, Issue 9672, Pages (April 2009)

A myriad of responses The Lancet Volume 358, (December 2001)

Costs of eliminating HIV in South Africa have been underestimated

Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28.

Volume 87, Issue 1, Pages (January 2015)

Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised.

Cholesterol and all-cause mortality in Honolulu

Political factors behind US global AIDS programmes slow-down

Autism, maths, and sex: the special triangle

Presentation transcript:

C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20 536 patients in the Heart Protection Study Heart Protection Study Collaborative Group The Lancet Volume 377, Issue 9764, Pages 469-476 (February 2011) DOI: 10.1016/S0140-6736(10)62174-5 Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 1 Effect of simvastatin allocation on vascular events by baseline concentration of C-reactive protein The Lancet 2011 377, 469-476DOI: (10.1016/S0140-6736(10)62174-5) Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 2 Effect of simvastatin allocation on vascular and non-vascular death by concentration of baseline C-reactive protein The Lancet 2011 377, 469-476DOI: (10.1016/S0140-6736(10)62174-5) Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 3 Effect of simvastatin allocation on first major vascular event during follow-up by baseline concentrations of LDL cholesterol and CRP Test for heterogeneity between four groups, excluding participants with missing data for baseline CRP concentration. Threshold values used to define low and high concentrations of LDL cholesterol and CRP are from the median values in the hypothesis-generating trial.8 CRP=C-reactive protein. The Lancet 2011 377, 469-476DOI: (10.1016/S0140-6736(10)62174-5) Copyright © 2011 Elsevier Ltd Terms and Conditions